Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed T1/T2 Response Independent of Differentiation.
10.1016/j.gpb.2019.03.002
- Author:
Iva XHANGOLLI
1
,
2
;
Burak DURA
1
,
2
;
GeeHee LEE
1
,
2
;
Dongjoo KIM
1
,
2
;
Yang XIAO
1
,
2
;
Rong FAN
1
,
3
,
4
Author Information
1. Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA
2. Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.
3. Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA
4. Yale Stem Cell Center, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: rong.fan@yale.edu.
- Publication Type:Journal Article
- Keywords:
CAR-T;
Single-cell proteomics;
Single-cell transcriptomics;
T cell activation
- MeSH:
Antigens;
metabolism;
CTLA-4 Antigen;
metabolism;
Cell Differentiation;
drug effects;
Cell Line;
Cytokines;
metabolism;
Cytotoxicity, Immunologic;
drug effects;
Granulocyte-Macrophage Colony-Stimulating Factor;
pharmacology;
Humans;
Lymphocyte Activation;
drug effects;
immunology;
Lymphocyte Subsets;
drug effects;
metabolism;
Phenotype;
Proteomics;
Receptors, Chimeric Antigen;
metabolism;
Single-Cell Analysis;
methods;
T-Lymphocytes, Regulatory;
drug effects;
metabolism;
Th1 Cells;
cytology;
drug effects;
Th2 Cells;
cytology;
drug effects;
Transcription, Genetic;
drug effects;
Up-Regulation;
drug effects
- From:
Genomics, Proteomics & Bioinformatics
2019;17(2):129-139
- CountryChina
- Language:English
-
Abstract:
The activation mechanism of chimeric antigen receptor (CAR)-engineered T cells may differ substantially from T cells carrying native T cell receptor, but this difference remains poorly understood. We present the first comprehensive portrait of single-cell level transcriptional and cytokine signatures of anti-CD19/4-1BB/CD28/CD3ζ CAR-T cells upon antigen-specific stimulation. Both CD4 helper T (T) cells and CD8 cytotoxic CAR-T cells are equally effective in directly killing target tumor cells and their cytotoxic activity is associated with the elevation of a range of T1 and T2 signature cytokines, e.g., interferon γ, tumor necrotic factor α, interleukin 5 (IL5), and IL13, as confirmed by the expression of master transcription factor genes TBX21 and GATA3. However, rather than conforming to stringent T1 or T2 subtypes, single-cell analysis reveals that the predominant response is a highly mixed T1/T2 function in the same cell. The regulatory T cell activity, although observed in a small fraction of activated cells, emerges from this hybrid T1/T2 population. Granulocyte-macrophage colony stimulating factor (GM-CSF) is produced from the majority of cells regardless of the polarization states, further contrasting CAR-T to classic T cells. Surprisingly, the cytokine response is minimally associated with differentiation status, although all major differentiation subsets such as naïve, central memory, effector memory, and effector are detected. All these suggest that the activation of CAR-engineered T cells is a canonical process that leads to a highly mixed response combining both type 1 and type 2 cytokines together with GM-CSF, supporting the notion that polyfunctional CAR-T cells correlate with objective response of patients in clinical trials. This work provides new insights into the mechanism of CAR activation and implies the necessity for cellular function assays to characterize the quality of CAR-T infusion products and monitor therapeutic responses in patients.
